A nine-year-old dancer was just weeks away from a life-threatening stroke after a tumour "bigger than a tennis ball" was ...
In our “Why I'm Running” series, Boston Marathon runners share what's inspiring them to make the 26.2-mile trek from ...
On-body injector delivery of subcutaneous teprotumumab achieves clinically meaningful proptosis reduction in phase 3 thyroid eye disease study.
Lung cancer remains the leading cause of cancer-related deaths worldwide, accounting for nearly one in five cancer deaths – ...
Evidence gaps include limited topline safety granularity, unknown long-term follow-up and retreatment rates, and lack of ...
The biotechnology company said Monday that its under-the-skin version of Tepezza met its primary endpoints in treating moderate-to-severe thyroid eye disease, showing a 77% proptosis response rate, ...
Discusses Positive Topline Results from Elegrobart REVEAL-1 Phase III Trial in Active Thyroid Eye Disease March 30, ...
Immunovant said on Thursday that its therapy to treat a type of eye disease failed to meet the main goals in a late-stage study.
Immunovant said on Thursday that its therapy failed to reduce eye bulging when tested in patients with moderate-to-severe ...
Viridian Therapeutics issued a press release that announced the positive elegrobart topline results from the phase 3 REVEAL-1 clinical trial in which the drug was evaluated to treat active thyroid eye ...
A subcutaneous monoclonal antibody induced greater reductions in proptosis at 24 weeks than placebo for people with active ...
A retrospective analysis of the patient's clinical data was conducted, including medical history, physical examination, imaging findings, treatment course, and outcomes. A 12-year-old female with CS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results